Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04871542 |
Recruitment Status :
Recruiting
First Posted : May 4, 2021
Last Update Posted : June 9, 2023
|
Tracking Information | |||||||
---|---|---|---|---|---|---|---|
First Submitted Date | April 29, 2021 | ||||||
First Posted Date | May 4, 2021 | ||||||
Last Update Posted Date | June 9, 2023 | ||||||
Actual Study Start Date | September 13, 2021 | ||||||
Estimated Primary Completion Date | September 30, 2025 (Final data collection date for primary outcome measure) | ||||||
Current Primary Outcome Measures |
Occurrence of severe or worse non-hematological immune-related adverse event (irAE) [ Time Frame: 52 weeks ] Adverse events will be recorded according to the physician rated Common Terminology Criteria for Adverse Events (CTCAE) scoring system.
|
||||||
Original Primary Outcome Measures | Same as current | ||||||
Change History | |||||||
Current Secondary Outcome Measures |
|
||||||
Original Secondary Outcome Measures |
|
||||||
Current Other Pre-specified Outcome Measures |
Feasibility of the Patient Cloud electronic (e)PRO app [ Time Frame: Up to 52 weeks ] Will be assessed by comparing the extent of missing data at each assessment time between participants choosing the Patient Cloud ePRO application (app) versus the use of paper forms. The participant experience of using the Patient Cloud ePRO app will also be assessed using a one-time questionnaire at the end of the participant's participation in the study
|
||||||
Original Other Pre-specified Outcome Measures |
Change in cytokine toxicity (CYTOX) score [ Time Frame: Baseline to 1 cycle after ICI-therapy ] The relationship between the CYTOX score and the occurrence of irAE will be evaluated using area under the curve (AUC). Separate evaluations will be conducted using both cytokine levels determined both prior to ICI-based therapy and after 1 cycle of ICI-based therapy.
|
||||||
Descriptive Information | |||||||
Brief Title | Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors | ||||||
Official Title | Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study | ||||||
Brief Summary | This study examines how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is the type of treatment that helps the body's immune system fight cancer. In the future, this information may help doctors make better decisions about cancer treatments. | ||||||
Detailed Description | PRIMARY OBJECTIVE: I. To both develop and independently validate a risk prediction model for Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher non-hematological immune-related adverse events (irAEs) in the first year of immune checkpoint inhibitor (ICI)-based therapy for the treatment of solid tumors. SECONDARY OBJECTIVES: I. To prospectively assess the incidence of any grade of non-hematological irAEs and grade 4 hematological irAEs on ICI-based therapy. II. To observe the trajectory of patient-reported quality of life and health preferences over 12 months. III. To observe the trajectory of patient-reported adverse events over 12 months using serial assessment with select Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) measures. IV. To measure the burden of chronic, grade 1 and 2 toxicities using methods such as toxicity over time (ToxT). V. To track patterns of treatment of irAEs and patterns of toxicity resolution. TRANSLATIONAL MEDICINE OBJECTIVES: I. To evaluate the cytokine toxicity (CYTOX) score, a composite measure derived from 11 different cytokine levels, both prior to ICI-based therapy and after 1 cycle of ICI-based therapy as a predictive signature for the development of irAEs. II. To establish a repository of archival tissue and blood/serum specimens for potential predictive and/or prognostic markers of irAE risk. ADDITIONAL OBJECTIVE: I. To assess the feasibility of using electronic (e)PRO in a multi-center clinical trial setting. OUTLINE: Patients undergo collection of a tissue sample at the start of their routine cancer treatment. Patients complete questionnaires at the start of cancer treatment, weeks 4, 12, 24, and 52. Patients will have the option of providing blood samples at several time points during the study. |
||||||
Study Type | Observational | ||||||
Study Design | Observational Model: Cohort Time Perspective: Prospective |
||||||
Target Follow-Up Duration | Not Provided | ||||||
Biospecimen | Retention: Samples With DNA Description: Tissue, blood, plasma, buffy coat
|
||||||
Sampling Method | Non-Probability Sample | ||||||
Study Population | Patients planning to receive ICI-based therapy for a solid tumor malignancy. | ||||||
Condition | Malignant Solid Neoplasm | ||||||
Intervention |
|
||||||
Study Groups/Cohorts | Observational (biospecimen collection, questionnaire)
Patients undergo collection of a tissue sample at the start of their routine cancer treatment. Patients complete questionnaires at the start of cancer treatment, weeks 4, 12, 24, and 52. Patients will have the option of providing blood samples at several time points during the study.
Interventions:
|
||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||
Recruitment Information | |||||||
Recruitment Status | Recruiting | ||||||
Estimated Enrollment |
2062 | ||||||
Original Estimated Enrollment | Same as current | ||||||
Estimated Study Completion Date | September 30, 2026 | ||||||
Estimated Primary Completion Date | September 30, 2025 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria | Inclusion Criteria:
|
||||||
Sex/Gender |
|
||||||
Ages | 18 Years and older (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers | No | ||||||
Contacts | |||||||
Listed Location Countries | United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number | NCT04871542 | ||||||
Other Study ID Numbers | S2013 NCI-2021-01262 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) S2013 ( Other Identifier: SWOG ) SWOG-S2013 ( Other Identifier: DCP ) S2013 ( Other Identifier: CTEP ) UG1CA189974 ( U.S. NIH Grant/Contract ) |
||||||
Has Data Monitoring Committee | Yes | ||||||
U.S. FDA-regulated Product |
|
||||||
IPD Sharing Statement | Not Provided | ||||||
Current Responsible Party | SWOG Cancer Research Network | ||||||
Original Responsible Party | Same as current | ||||||
Current Study Sponsor | SWOG Cancer Research Network | ||||||
Original Study Sponsor | Same as current | ||||||
Collaborators | National Cancer Institute (NCI) | ||||||
Investigators |
|
||||||
PRS Account | SWOG Cancer Research Network | ||||||
Verification Date | June 2023 |